Inside mFlusiva: The FDA’s First mRNA Flu Vaccine Explained

Introduction to the Evolving Influenza Landscape

Seasonal influenza represents a persistent and highly disruptive public health challenge, responsible for hundreds of thousands of hospitalizations and tens of thousands of fatalities annually in the United States alone¹. Historically, the burden of severe disease, secondary bacterial pneumonia, and the exacerbation of underlying chronic comorbidities has fallen disproportionately upon older adults. Epidemiological data indicates that individuals aged 65 and older account for approximately 57 percent of influenza-related hospitalizations and upwards of 71 to 85 percent of all influenza-related deaths during typical respiratory virus seasons³. For decades, the cornerstone of influenza prevention has relied upon traditional vaccine manufacturing platforms, primarily the propagation of vaccine viruses in embryonated chicken eggs or, more recently, in mammalian cell cultures⁵.

While these traditional platforms have undoubtedly saved millions of lives, they are encumbered by significant biological, logistical, and immunological limitations. The most pressing logistical vulnerability of traditional egg-based manufacturing is the extended production timeline, which typically mandates a six-month lead time³. This extensive manufacturing window requires global health authorities to select and lock in target vaccine strains months before the actual onset of the influenza season. If the circulating wild-type strains undergo antigenic drift during this prolonged window, the resulting mismatch between the vaccine and the circulating virus can severely compromise vaccine effectiveness, leaving vulnerable populations exposed⁸.

In a regulatory decision that promises to modernize this entrenched paradigm, the U.S. Food and Drug Administration (FDA) approved mFlusiva (internally designated during clinical development as mRNA-1010) on August 5, 2026¹¹. Developed by Moderna, mFlusiva is the first messenger RNA (mRNA)-based seasonal influenza vaccine authorized for active immunization in the United States¹¹. Approved for adults aged 50 and older, the vaccine utilizes the same foundational lipid nanoparticle and mRNA architecture that proved instrumental in curtailing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic¹. The introduction of an mRNA influenza vaccine offers the potential to condense the manufacturing timeline from six months to approximately two to three months, thereby allowing strain selection to occur much closer to the season's onset and theoretically ensuring a higher fidelity match with circulating strains³.

This report provides an exhaustive examination of mFlusiva, detailing its underlying molecular composition, the immunological mechanisms that differentiate it from traditional platforms, its clinical efficacy and safety profiles, and the complex regulatory pathway that preceded its approval.

The Structural Biology of Egg Adaptation

To fully appreciate the clinical utility of an mRNA-based influenza vaccine, it is necessary to understand the inherent biological flaws of traditional egg-based manufacturing. The structural biology of the influenza hemagglutinin (HA) protein is highly sensitive to the host environment in which the virus replicates⁵. When human influenza viruses—particularly the A/H3N2 subtype—are grown in avian cells within chicken eggs, the virus is subjected to intense selective pressure. Consequently, the virus frequently acquires egg-adaptive mutations to optimize its binding to avian alpha-2,3-linked sialic acid receptors rather than the alpha-2,6-linked sialic acid receptors preferred by human influenza strains⁵.

The HA receptor-binding site partially overlaps with several major antigenic sites. A prominent example of this phenomenon is the L194P mutation, one of the most common egg-adaptive mutations observed in H3N2 vaccine seed strains¹⁸. The substitution of leucine with proline at amino acid position 194 significantly alters the three-dimensional conformation of the receptor-binding site, thereby fundamentally changing the antigenicity of the HA protein¹⁷. When a traditional vaccine containing the L194P mutation is administered, the human host produces neutralizing antibodies against this altered, avian-adapted conformation. Unfortunately, these antibodies often exhibit substantially reduced neutralization capacity against the circulating wild-type human H3N2 virus, which lacks the L194P mutation¹⁷.

Furthermore, the preference for specific egg-adaptation pathways is highly strain-dependent and influenced by the pre-existing genetic landscape of the virus. For instance, the presence of specific amino acids like threonine at position 160 (T160) and asparagine at position 190 (N190)—which are prevalent in many recent human H3N2 strains—has been shown to restrict the emergence of the L194P mutation, while remaining compatible with other adaptive mutations like G186V¹⁷. This complex epistasis makes standardizing egg-based vaccine seed strains highly unpredictable.

Because mRNA vaccines instruct the human host's own cells to synthesize the HA protein directly from a precisely engineered genetic sequence, the antigen produced is an exact structural match to the intended wild-type virus³. This high-fidelity, intracellular antigenic presentation avoids the structural distortions introduced by egg adaptation entirely, leading to a highly targeted and effective humoral response¹⁶.

Molecular Composition and Lipid Nanoparticle Architecture

mFlusiva operates by delivering the genetic instructions required for the host's cellular machinery to synthesize the viral antigen in vivo⁷. The vaccine is completely free of egg protein, antibiotics, and preservatives, and relies on a purely synthetic manufacturing process⁶.

Trivalent mRNA Configuration

The 2026-2027 formulation of mFlusiva is a trivalent vaccine containing three distinct mRNA sequences. Each sequence encodes the full-length hemagglutinin surface glycoprotein of a specific influenza strain recommended by the World Health Organization and the FDA for the upcoming season⁵. The three targeted strains include two Influenza A lineages and one Influenza B lineage, specifically: an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Michigan/105/2025 (H3N2)-like virus, and a B/Pennsylvania/19/2025 (B/Victoria lineage)-like virus⁶.

The vaccine is formulated as a sterile suspension and administered as a single 0.38 milliliter intramuscular injection. Within this volume, there is a total of 37.5 micrograms of mRNA, distributed equally as 12.5 micrograms for each of the three targeted viral strains¹².

The SM-102 Lipid Nanoparticle Delivery System

Naked mRNA is highly unstable and is rapidly degraded by ubiquitous extracellular ribonucleases. Consequently, it requires a robust delivery vehicle to safely traverse the extracellular space and facilitate cellular endocytosis¹⁶. mFlusiva utilizes a proprietary lipid nanoparticle (LNP) delivery system that is structurally homologous to the one utilized in Moderna's COVID-19 vaccine platform²⁴.

Each 0.38 milliliter dose contains 0.759 milligrams of total lipid¹². The LNP architecture is meticulously engineered, relying on a specific molar ratio of four distinct lipid components—typically a ratio of 50 to 10 to 38.5 to 1.5²⁴. These components serve specialized functions:

1. Ionizable Cationic Lipid (SM-102): Representing 50 percent of the lipid molarity, SM-102 is the primary functional component. It remains electrostatically neutral at physiological pH, which limits systemic toxicity and reduces premature immune clearance in the bloodstream. However, upon cellular uptake via endocytosis, the acidic environment of the endosome protonates the lipid, giving it a positive charge. This charge shift facilitates electrostatic interactions with the anionic endosomal membrane, leading to membrane disruption and allowing the mRNA to escape into the cytoplasm before undergoing lysosomal degradation²¹.

2. Helper Phospholipid (DSPC): 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) makes up 10 percent of the lipid content. As a zwitterionic lipid, DSPC promotes the formation of the lipid bilayer, closely mimicking natural cellular membranes and stabilizing the overall LNP structure¹².

3. Cholesterol: Comprising 38.5 percent of the lipid molarity, cholesterol is incorporated to fill structural gaps in the lipid bilayer. It regulates membrane fluidity, enhances the structural integrity of the nanoparticle, and prevents the premature leakage of the encapsulated mRNA cargo¹².

4. PEGylated Lipid (PEG 2000 DMG): Polyethylene glycol 2000 dimyristoyl glycerol makes up the remaining 1.5 percent. This lipid coats the exterior of the LNP, providing a hydrophilic steric barrier. This prevents the nanoparticles from aggregating in solution and shields them from rapid opsonization and clearance by phagocytic immune cells, effectively extending their pharmacokinetic half-life¹².

To achieve optimal encapsulation efficiency and homogenous nanoparticle size, the manufacturing process relies on microfluidic mixing devices. In these systems, an aqueous buffer containing the mRNA and an ethanolic mixture containing the lipids are combined at rapid flow rates (e.g., 12 milliliters per minute) in a precise three-to-one volumetric ratio. This controlled, rapid mixing induces immediate lipid precipitation around the mRNA, forming monodisperse nanoparticles²⁴. Additional pharmaceutical excipients include tromethamine and tromethamine hydrochloride, which act as buffering agents to maintain optimal pH, and sucrose, which serves as a cryoprotectant to preserve LNP stability during prolonged refrigerated storage at 2 to 8 degrees Celsius¹².

Immunological Mechanisms: Humoral and Cellular Synergy

The transition from inactivated proteins to an mRNA platform fundamentally alters the kinetics and depth of immune priming, eliciting a response that closely mimics natural viral infection.

Stalk-Reactive Humoral Immunity

Upon administration, the LNP-encapsulated mRNA is primarily taken up by resident antigen-presenting cells (APCs), such as dendritic cells and macrophages, as well as local myocytes at the injection site. Following translation, the viral hemagglutinin antigens are displayed on the cell surface, where they are recognized by naive B cells².

Current seasonal influenza vaccines are highly proficient at inducing neutralizing antibodies against the immunodominant globular head domain of the HA protein (HA1)²⁶. Classically, five distinct antigenic sites on the HA head—designated Sb, Sa, Cb, Ca1, and Ca2—are the primary targets of the vaccine-induced humoral response²⁶. However, the HA head is highly variable and undergoes constant antigenic drift, necessitating annual vaccine reformulation.

Recent serological analyses reveal that mRNA-based influenza vaccines facilitate the induction of cross-reactive antibodies directed against the more highly conserved stalk domain (HA2) of the hemagglutinin protein²⁶. The HA stalk domain remains structurally conserved between diverse influenza strains due to functional restraints related to viral membrane fusion and historically low immune pressure²⁶. Stalk-directed antibodies provide broad, cross-strain protection by physically impairing endosomal membrane fusion and interrupting HA maturation²⁶.

Vaccinees under 65 years of age generally exhibit significant increases in anti-stalk antibodies, particularly against Group 1 hemagglutinins (which include H1 subtypes)²⁶. The intracellular expression and natural, trimeric folding of the HA protein mediated by mRNA technology appear to enhance the presentation of these subdominant stalk epitopes. However, studies indicate that the magnitude of this cross-reactive stalk response is subject to age-related immunosenescence, with the lowest anti-stalk antibody titers observed in the oldest cohorts (individuals aged 80 and older), underscoring the ongoing challenge of generating broad humoral protection in the elderly²⁶.

Cellular Immunity: CD4+ and CD8+ T-Cell Dynamics

While traditional inactivated vaccines excel at stimulating antibody production, they are relatively inefficient at inducing cytotoxic T-cell responses because the exogenous proteins do not efficiently enter the Major Histocompatibility Complex (MHC) Class I antigen-presentation pathway²⁸. In stark contrast, the endogenous production of HA proteins via mRNA translation allows the antigen to be degraded by the proteasome and presented on MHC Class I molecules, while simultaneously being processed through the MHC Class II pathway³⁰.

Clinical data demonstrates that mRNA-1010 generates a highly robust, antigen-specific CD4+ T-cell response²⁹. This response is highly heterogeneous, heavily dominated by T-helper 1 (Th1) cells that express the T-bet transcription factor and secrete pro-inflammatory cytokines, most notably interferon-gamma (IFN-gamma)²⁸. Additionally, significant populations of T follicular helper (Tfh) cells (expressing Bcl-6) and regulatory T cells (expressing Foxp3) are induced²⁹. These CD4+ cells are crucial orchestrators of the local immune environment. Tfh cells provide essential help to B cells within germinal centers for antibody affinity maturation, while specialized CD4+ tissue-resident memory (TRM) cells seed the upper respiratory tract to orchestrate rapid local responses upon subsequent viral exposure²⁹. Advanced immunological tracking using surrogate markers such as CD49d and CD11a has confirmed that the complete endogenous CD4+ T-cell response to mRNA vaccination is highly diverse and spans multiple epitopes across the synthesized viral proteins²⁹.

Furthermore, mRNA-1010 has demonstrated a trend toward eliciting higher CD8+ cytotoxic T-cell responses compared to traditional adjuvanted vaccines³¹. CD8+ T-cells act to clear intracellular infections by recognizing conserved viral epitopes and directly lysing infected host cells³⁰. A critical, yet paradoxical, aspect of this process involves the regulatory role of IFN-gamma. Research indicates that IFN-gamma signaling actively downregulates the expression of the Interleukin-7 receptor on activated CD8+ T-cells, thereby promoting the contraction phase of the effector T-cell population³⁴. By carefully regulating this contraction, the immune system prevents excessive immunopathology in the lungs while simultaneously fostering the optimal formation of a durable memory precursor pool³⁰. This intricate balance of cellular immunity provides cross-reactive defense mechanisms that persist even when circulating influenza viruses undergo extensive antigenic drift in their surface proteins³⁰.

Clinical Efficacy: From Early Trials to the FLUENT Study

The clinical development of mFlusiva underwent several iterative phases to optimize immunogenicity, culminating in the data that supported its regulatory approval.

Early Immunogenicity Trials and Formulation Refinement

The initial Phase 3 trials of the mRNA-1010 candidate (designated P301 and P302) evaluated the safety and immunogenicity of a quadrivalent formulation in both younger and older adult populations. While the early formulations successfully boosted hemagglutination inhibition (HAI) titers against Influenza A strains (H1N1 and H3N2), demonstrating superiority or non-inferiority to standard comparators, they failed to meet pre-specified statistical non-inferiority criteria for the Influenza B lineages (B/Victoria and B/Yamagata)³⁶. Furthermore, an early efficacy analysis did not accrue the target number of cases to demonstrate protocol-defined statistical non-inferiority across all strains³⁷.

In response to these findings, Moderna initiated the P303 (IGNITE) trial, utilizing an optimized formulation designed to increase immune responses, particularly against the B strains. The optimized mRNA-1010 formulation successfully met all primary immunogenicity endpoints, exhibiting higher geometric mean titers and superior seroconversion rates across all included strains relative to the standard dose vaccine³⁷.

The P304 (FLUENT) Efficacy Trial

The regulatory approval of mFlusiva for adults aged 50 to 64 was firmly rooted in the clinical efficacy data generated by the pivotal Phase 3 FLUENT trial (NCT06602024; also known as P304)²².

The FLUENT trial was a randomized, observer-blind, active-controlled, case-driven study involving 40,805 participants aged 50 years and older. The trial was conducted across 301 sites in 11 countries across the Northern Hemisphere during the 2024-2025 influenza season⁹. Participants were randomly assigned in a one-to-one ratio to receive a single dose of either the trivalent mFlusiva or a licensed, standard-dose active comparator vaccine³⁹.

The primary efficacy endpoint was the relative vaccine efficacy (rVE) of mFlusiva compared to the standard-dose vaccine in preventing the first episode of reverse-transcriptase polymerase chain reaction (RT-PCR)-confirmed, protocol-defined influenza-like illness caused by any influenza A or B strain⁵. The protocol definition of influenza-like illness required at least one systemic symptom (such as temperature greater than 37.2 degrees Celsius, chills, fatigue, headaches, or myalgia) and at least one respiratory symptom (such as sore throat, cough, sputum production, wheezing, or difficulty breathing)⁴².

The trial successfully met its prespecified criteria for non-inferiority, superiority, and higher-level superiority. In the per-protocol efficacy analysis, RT-PCR-confirmed influenza-like illness occurred in 2.0 percent of the mFlusiva recipients (411 out of 20,179) compared to 2.8 percent of the standard-dose comparator recipients (557 out of 20,124)⁵. This corresponded to an overall relative vaccine efficacy of 26.6 percent²². When utilizing the modified Centers for Disease Control and Prevention (CDC) definition for the secondary endpoint, the relative vaccine efficacy remained robust at 23.5 percent⁴⁶.

Efficacy Subgroup / Strain	Relative Vaccine Efficacy (rVE)	95% Confidence Interval
Overall Population (≥ 50 years)	26.6%	16.7% to 35.4%
Age: 50 through 64 years	26.1%	12.3% to 37.7%
Age: 65 years and older	27.4%	12.1% to 40.0%
Age: 65 through 74 years	28.0%	10.4% to 42.2%
Age: 75 years and older	25.3%	-10.4% to 49.5%
Strain: A/H1N1	29.6%	Not provided
Strain: A/H3N2	22.2%	Not provided
Strain: B/Victoria	29.1%	Not provided

Table 1: Relative Vaccine Efficacy (rVE) of mFlusiva compared to a standard-dose licensed influenza vaccine for the prevention of RT-PCR-confirmed influenza-like illness. Data derived from primary clinical summaries¹².

Beyond the prevention of mild-to-moderate illness, exploratory analyses indicated that mFlusiva resulted in a numerical reduction in higher-level medical interventions. For severe outcomes—defined comprehensively as urgent care visits, emergency department admissions, and hospitalizations—the relative vaccine efficacy rose to an impressive 47.9 percent, although the study was not initially powered to establish definitive statistical significance for these combined secondary endpoints³⁹.

Reactogenicity and Safety Profile

The profound immunological activation characteristic of mRNA vaccines, while highly beneficial for efficacy, inherently results in higher reactogenicity—the expected, temporary physical manifestations of a robust inflammatory immune response⁸.

In the Phase 3 trials, the safety profile of mFlusiva was scrutinized closely against the active comparators. Overall, the vaccine demonstrated an acceptable safety profile across more than 14,000 adult participants, with no new safety signals identified and no cases of myocarditis or pericarditis linked to the vaccine within the 42-day risk window¹⁶.

However, solicited local and systemic adverse events occurred at a significantly higher frequency in the mFlusiva cohorts compared to those receiving traditional inactivated vaccines⁵.

Solicited Adverse Reaction	mFlusiva Incidence (%)	Standard-Dose Comparator Incidence (%)
Local Reactions
Injection-site pain	65.8%	29.8%
Axillary (underarm) swelling/tenderness	20.3%	Not reported
Systemic Reactions
Fatigue	45.1%	20.3%
Headache	37.8%	18.0%
Myalgia (Muscle ache)	35.4%	11.6%
Arthralgia (Joint pain)	31.5%	Not reported
Chills	27.5%	Not reported

Table 2: Comparison of solicited adverse reactions occurring within 7 days of vaccination among adults aged 50-64. Note: Reactogenicity was observed to be slightly lower in frequency and severity in the 65 and older cohort.⁵.

The vast majority of these solicited reactions were classified as mild to moderate (Grade 1 or 2) in severity. They proved to be transient, typically featuring a median onset of 2 days post-vaccination and a median duration of 1 to 2 days³⁹.

Crucially, the rate of severe, unsolicited, or serious adverse events (SAEs) remained highly comparable between the two groups. SAEs were reported in 2.2 percent of mFlusiva recipients and 1.9 percent of standard-dose comparator recipients. Only a minute fraction of these events (three in the mRNA group and two in the comparator group) were determined by clinical investigators to be causally related to the vaccines²³. The clinical consensus maintains that the transient reactogenicity of mFlusiva represents an acceptable clinical trade-off for the superior relative efficacy it provides in preventing laboratory-confirmed influenza⁸.

A Turbulent Regulatory Pathway and Policy Implications

The journey to FDA approval for mFlusiva was fraught with complex regulatory maneuvering, philosophical debates over clinical trial design, and shifting public health policies, underscoring the intense scrutiny currently applied to next-generation vaccine platforms.

The Refusal-to-File Dispute

In early 2026, Moderna's initial Biologics License Application (BLA) met unexpected resistance when the FDA's Center for Biologics Evaluation and Research (CBER) issued a Refusal-to-File (RTF) letter³. The letter, signed by then-CBER Director Vinay Prasad amidst a broader climate of heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr., effectively blocked the application from proceeding to formal review¹.

The regulatory impasse did not center on safety concerns or the raw efficacy data itself. Instead, CBER objected to the clinical trial design used to evaluate the older adult cohort (65 years and older) in the FLUENT efficacy trial. Because the trial utilized a standard-dose vaccine as the active comparator rather than a high-dose or adjuvanted vaccine (which is the preferentially recommended standard of care for seniors in the U.S.), the agency argued that the submitted data was insufficient to prove definitive clinical benefit over the best available therapy for that specific demographic⁵².

Moderna publicly contested the RTF letter, highlighting a perceived inconsistency in regulatory guidance. The company pointed out that the FDA had previously reviewed and approved the Phase 3 protocol designs prior to the trial's initiation. Furthermore, Moderna noted that they had proactively conducted a separate immunogenicity study (the P303 IGNITE trial) specifically comparing mFlusiva to a high-dose vaccine to bridge this exact evidential gap⁸. While former FDA Commissioner Marty Makary argued that the company had ignored clear agency guidance regarding comparator selection, the standoff was ultimately short-lived. Following intense scientific discourse, the FDA reversed its decision days later and accepted the amended, age-stratified application for review¹.

Stratified Approval and the VRBPAC Endorsement

To satisfy the stringent regulatory requirements while bringing the vaccine to market, a bifurcated, age-stratified regulatory strategy was adopted.

In June 2026, the FDA's independent Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened to evaluate the totality of the data. The meeting occurred during a period of significant upheaval in the vaccine sector, following the controversial dismissal and replacement of members of the Advisory Committee on Immunization Practices (ACIP)⁵². Despite the charged political atmosphere, the VRBPAC panelists—including prominent infectious disease experts—praised the robust immunogenicity data, the strong T-cell responses, and the clean safety profile. The committee voted unanimously (9-0) that the benefits of mFlusiva outweighed the risks for all adults aged 50 and older¹.

Consequently, on August 5, 2026, the FDA granted approval through two distinct regulatory pathways:

1. Full (Traditional) Approval for adults aged 50 through 64. This clearance was backed directly by the clinical efficacy data from the FLUENT trial, which demonstrated clear superiority over standard-dose comparators in preventing influenza illness¹.

2. Accelerated Approval for adults aged 65 and older. This clearance was based on surrogate immunogenicity endpoints from the IGNITE trial comparing mFlusiva to a high-dose vaccine, supported by the descriptive relative efficacy data. As a mandatory condition of the accelerated approval pathway, Moderna is legally bound to conduct an extensive, multi-year, postmarketing confirmatory trial against a high-dose comparator (involving upwards of 400,000 seniors) to definitively verify the clinical benefit in this highly vulnerable population¹.

Future Horizons: Combination Vaccines and Pandemic Preparedness

The successful licensure of mFlusiva serves as a critical clinical validation of the mRNA platform for respiratory viruses beyond SARS-CoV-2 and paves the way for the next iteration of preventative medicine: multicomponent combination vaccines.

Moderna is currently advancing mRNA-1083, a single-injection combination vaccine that merges the seasonal influenza components of mFlusiva (mRNA-1010) with their next-generation COVID-19 vaccine candidate (mRNA-1283)²⁵. Recent Phase 3 trial data (NCT06097273) evaluating mRNA-1083 against the co-administration of separate, licensed standard-of-care vaccines (Fluzone HD and Spikevax in the 65 and older cohort) yielded highly promising results²⁵.

The mRNA-1083 combination vaccine elicited statistically significantly higher immune responses against both targeted COVID-19 variants and multiple influenza strains. For instance, in the 65 and older cohort, the Geometric Mean Ratios (GMRs) of the mRNA-1083 group compared to the Fluzone HD group were 1.155 for the A/H1N1 strain, 1.063 for the A/H3N2 strain, and 1.118 for the B/Victoria strain²⁵. Concurrently, the GMR for the SARS-CoV-2 variant Omicron XBB.1.5 was 1.641 compared to Spikevax²⁵. The introduction of highly efficacious combination vaccines has the potential to dramatically reduce logistical burdens on healthcare systems and pharmacies. By streamlining patient compliance, these multicomponent vaccines could effectively counter the rising tide of vaccine hesitancy and "shot fatigue" observed in the post-pandemic era²⁵.

Furthermore, from a global biosecurity standpoint, the maturation of mRNA influenza vaccine infrastructure is invaluable. In the event of a novel zoonotic influenza pandemic—such as an H5 or H7 avian strain crossing over to humans with sustained transmission—the ability to sequence the pathogen and manufacture scalable, highly matched lipid nanoparticle mRNA vaccines in a matter of weeks provides a critical defensive mechanism that rigid, egg-based infrastructure cannot match¹.

Conclusion

The FDA approval of mFlusiva marks a watershed moment in the field of vaccinology, fundamentally shifting the paradigm of seasonal influenza prevention. By leveraging lipid nanoparticle mRNA technology, mFlusiva successfully bypasses the severe biological constraints of traditional egg-based manufacturing, preventing structural egg-adaptive mutations and allowing for a significantly more rapid and precise antigenic match.

The extensive clinical data generated by the Phase 3 FLUENT trial conclusively demonstrates that mFlusiva provides superior relative efficacy in preventing confirmed influenza illness in older adults when compared to standard-dose inactivated vaccines. While the intracellular translation of viral antigens inherently induces higher rates of transient local and systemic reactogenicity, the overall adverse event profile remains well within the bounds of clinical acceptability. This reactogenicity is balanced by a substantial enhancement in both humoral and cellular immunity, particularly the induction of critical cross-reactive T-cell responses that traditional vaccines struggle to mount.

Despite a complex and highly scrutinized regulatory pathway complicated by philosophical debates over trial comparators and shifting political tides, the successful, age-stratified authorization of mFlusiva secures a potent new tool for protecting older adults against seasonal influenza. More broadly, the validation of this platform solidifies the foundation for a future dominated by rapidly adaptable, highly efficacious, and combined respiratory mRNA vaccines, ensuring enhanced readiness for both seasonal epidemics and future pandemic threats.

Works cited

1. New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine, https://apnews.com/article/flu-vaccine-moderna-mrna-fda-mflusiva-59d991a6bf70c26e2f0c210cc8ca87f1

2. FDA panel backs first-of-its-kind flu vaccine using mRNA technology, https://apnews.com/article/moderna-flu-vaccine-mrna-fda-advisers-mflusiva-488c68fe39244ca5ebad441a815b4ba2

3. FDA Approves Moderna's mRNA Flu Vaccine After Phase 3 Success, https://www.ajmc.com/view/fda-approves-moderna-s-mrna-flu-vaccine-after-phase-3-success

4. FDA Approves Moderna's mRNA-Based Flu Vaccine | PharmExec, https://www.pharmexec.com/view/fda-moderna-mrna-based-flu-vaccine

5. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults, https://www.medschool.umaryland.edu/media/som/offices-of-the-dean/student-affairs/documents/address-pdfs/Efficacy-and-Safety-of-an-mRNA-Seasonal-Influenza-Vaccine-in-Adults.pdf

6. mFlusiva mRNA Flu Vaccine: Is It FDA-Approved for Adults Over 50?, https://passionhealthphysicians.com/mflusiva-mrna-flu-vaccine/

7. 5 things to know about Moderna’s new mRNA flu vaccine, https://triblive.com/local/regional/5-things-to-know-about-modernas-new-mrna-flu-vaccine/

8. FDA panel backs first-of-its-kind flu vaccine using mRNA technology, https://www.ap.org/news-highlights/spotlights/2026/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology/

9. Moderna's mRNA-1010 Flu Vaccine Proves Superior Efficacy in, https://www.patientcareonline.com/view/moderna-s-mrna-1010-flu-vaccine-proves-superior-efficacy-in-pivotal-late-stage-trial

10. Moderna announces promising efficacy results from mRNA flu, https://www.cidrap.umn.edu/influenza-vaccines/moderna-announces-promising-efficacy-results-mrna-flu-vaccine-trial

11. FDA approves Moderna’s mRNA flu vaccine, https://www.biopharmadive.com/news/moderna-fda-approve-mflusiva-seasonal-influenza/826864/

12. MFlusiva Flu Vaccine: Uses, Dosage, Side Effects, Warnings, https://www.drugs.com/mflusiva.html

13. FDA Approves mFLUSIVA (influenza vaccine, mRNA) for the, https://www.drugs.com/newdrugs/fda-approves-mflusiva-influenza-vaccine-mrna-prevention-seasonal-influenza-6855.html

14. FDA Approves mFLUSIVA, First mRNA-Based Flu Vaccine, https://www.drugtopics.com/view/fda-approves-mflusiva-first-mrna-based-flu-vaccine

15. New flu vaccine mFlusiva is approved for older people - KIRO 7, https://www.kiro7.com/news/business/new-kind-flu-shot-is/722UWWKK6Y2I3OTCRP5YGLGQQM/?outputType=amp

16. An mRNA-based seasonal influenza vaccine in adults - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11970786/

17. Egg-adaptation pathway of human influenza H3N2 virus is ... - bioRxiv, https://www.biorxiv.org/content/10.1101/2022.01.31.478576v1.full-text

18. Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2, https://pubmed.ncbi.nlm.nih.gov/31151913/

19. Egg-adaptive mutations of human influenza H3N2 virus are ... - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9536752/

20. A clinical trial of an investigational seasonal flu vaccine for adults, https://connect.trialscope.com/studies/cb1608e3-ebd6-49d9-9b61-9743cca11bb3

21. Information For Recipients and Caregivers - MFLUSIVA - FDA, https://www.fda.gov/media/194126/download?attachment

22. Moderna's mRNA-1010 Shows Efficacy in Phase 3 Seasonal Flu, https://www.contagionlive.com/view/moderna-s-mrna-1010-shows-efficacy-in-phase-3-seasonal-flu-vaccine-trial

23. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults, https://www.researchgate.net/publication/405239356_Efficacy_and_Safety_of_an_mRNA_Seasonal_Influenza_Vaccine_in_Adults

24. SM-102 (GMP) | MedChemExpress, https://file.medchemexpress.com/batch_PDF/HY-134541G/SM-102-GMP-DataSheet-MedChemExpress.pdf

25. Moderna Reports Phase 3 Results for Flu-COVID Combo Vaccine, https://respiratory-therapy.com/products-treatment/pharmaceuticals/us-pharmaceuticals/moderna-reports-positive-phase-3-results-flu-covid-combo-vaccine/

26. Group 1 and group 2 hemagglutinin stalk antibody response, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1194073/full

27. Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA, https://www.mdpi.com/2076-393X/13/2/140

28. The CD4 T Cell Response against Influenza A Virus - MDPI, https://www.mdpi.com/2073-4409/13/7/639

29. Kinetics and Phenotype of the CD4 T Cell Response to Influenza, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02351/full

30. A universal influenza mRNA vaccine candidate boosts T cell ... - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9750153/

31. An mRNA influenza vaccine induces immunity comparable to ... - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12901179/

32. Nasal tissue-resident memory CD4+ T cells persist after influenza A, https://www.biorxiv.org/content/10.1101/2024.07.06.602325v2.full-text

33. Investigation of CD4 and CD8 T cell-mediated protection against, https://pmc.ncbi.nlm.nih.gov/articles/PMC9301821/

34. Gamma Interferon Regulates Contraction of the Influenza Virus, https://pmc.ncbi.nlm.nih.gov/articles/PMC3838152/

35. Gamma Interferon Regulates Contraction of the Influenza Virus, https://www.semanticscholar.org/paper/Gamma-Interferon-Regulates-Contraction-of-the-CD8-T-Prabhu-Ho/28c1dc77b007be0d064251c8cd1ac07005c08fef

36. Moderna's mRNA-1010 seasonal flu vaccine yields mixed results, https://firstwordpharma.com/story/5707315

37. Flu vaccines (mRNA-1010/-20/-30/-11 - Moderna Presentation, https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2024/flu-11-02-23.pdf

38. Flu Vaccine Trials Show Safety and Immune Response - EMJ, https://www.emjreviews.com/allergy-immunology/news/flu-vaccine-trials-show-safety-and-immune-response/

39. Phase 3 Trial Finds Moderna's mRNA-1010 Influenza Vaccine, https://www.appliedclinicaltrialsonline.com/view/moderna-mrna-1010-influenza-vaccine-

40. NCT06602024 | A Study of mRNA-1010 Compared With a Licensed, https://clinicaltrials.gov/study/NCT06602024

41. Moderna Receives U.S. FDA Approval for Influenza Vaccine, https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025&symbol=MRNA

42. FDA Review of Efficacy, Immunogenicity, and Safety of mFlusiva, https://www.fda.gov/media/193214/download

43. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults, https://pubmed.ncbi.nlm.nih.gov/42090792/

44. NCT05827978 | Study of mRNA-1010 Seasonal Influenza Vaccine, https://clinicaltrials.gov/study/NCT05827978

45. FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine, https://www.pharmacytimes.com/view/fda-approves-mflusiva-the-first-mrna-based-influenza-vaccine

46. mRNA-1010 Shows Superior Influenza Vaccine Efficacy in Adults, https://www.consultant360.com/exclusive/mrna-1010-shows-superior-influenza-vaccine-efficacy-adults-50-vs-standard-vaccines

47. Moderna Announces Positive Phase 3 Results for Seasonal, https://feeds.issuerdirect.com/news-release.html?newsid=4899326521164266&symbol=MRNA

48. FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu, https://www.biopharminternational.com/view/fda-advisory-panel-votes-9-0-in-favor-of-moderna-s-mrna-flu-vaccine-setting-stage-for-august-decision

49. Package Insert and Information for Patients - MFLUSIVA - FDA, https://www.fda.gov/media/194120/download?attachment

50. Package Insert and Information for Patients - MFLUSIVA - FDA, https://www.fda.gov/media/194120/download

51. Moderna's mFLUSIVA Approval Validates mRNA Platform Beyond, https://www.biopharminternational.com/view/moderna-mflusiva-approval-validates-mrna-platform-beyond-covid-19-what-it-means-for-biopharmaceutical-manufacturing

52. US approves Moderna's mRNA flu vaccine after FDA review battle, https://firstwordpharma.com/story/7821538

53. FDA rejects Moderna's filing for mRNA-1010 flu vaccine, https://www.bioanalysis-zone.com/fda-rejects-modernas-filing-for-mrna-1010-flu-vaccine/

54. Moderna's mRNA flu shot outperforms current standard at Phase III, https://www.clinicaltrialsarena.com/news/moderna-mrna-flu-outperforms-current-standard-phase-iii/

55. Vaccines and Related Biological Products Advisory Committee - FDA, https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee/roster-vaccines-and-related-biological-products-advisory-committee

56. Multicomponent COVID-19/Influenza Vaccine Induces Higher, https://www.pharmacytimes.com/view/multicomponent-covid-19-influenza-vaccine-induces-higher-immune-responses-than-standard-care-immunizations

57. Immunogenicity and Safety of Influenza and COVID-19 ... - PubMed, https://pubmed.ncbi.nlm.nih.gov/40332892/

58. A Study of mRNA‑1083 (SARS‑CoV‑2 and Influenza) Vaccine in, https://trials.modernatx.com/study/?id=mRNA-1083-P301